drugset
drugset / Trial / NCT07438886

Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers

NCT07438886 ↗

Phase 1 Not yet recruiting 16 enrolled Advenchen Laboratories, LLC
NaSingle-groupOpen-labelTreatment

Summary

This is a non-randomized, open-label, fixed-sequence drug-drug interaction study to evaluate the effects of itraconazole and ticagrelor on the pharmacokinetics of catequentinib hydrochloride (AL3818) in healthy volunteers.

Timeline

Start
2026-03-02
Primary completion
2027-03-31
Completion
2027-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 8 mg —
Subject Itraconazole Small molecule 200 mg Oral
Subject Ticagrelor Small molecule 90 mg Oral

Indications

No indication recorded.